Evaluation of the Safety and Compliance of 3-Week Cycles of Vinorelbine on Days 1 and 8 and Cisplatin on Day 1 as Adjuvant Chemotherapy in Japanese Patients with Completely Resected Pathological Stage IB to IIIA Non-small Cell Lung Cancer: A Retrospective Study

2008 ◽  
Vol 39 (3) ◽  
pp. 158-162 ◽  
Author(s):  
T. Shukuya ◽  
T. Takahashi ◽  
A. Tamiya ◽  
A. Ono ◽  
S. Igawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retrospective Study ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Japanese Patients ◽  
Small Cell ◽  
Pathological Stage ◽  
Small Cell Lung ◽  
Stage Ib

scholarly journals Safety of Adjuvant Chemotherapy with Carboplatin and Weekly Paclitaxel for Pathological Stage IB-IIIB Non-small Cell Lung Cancer

Haigan ◽  
2011 ◽  
Vol 51 (3) ◽  
pp. 165-170 ◽  
Author(s):  
Yoshio Okano ◽  
Hiroyuki Hino ◽  
Mitsuteru Yoshida ◽  
Nobuo Hatakeyama ◽  
Tsutomu Shinohara ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Weekly Paclitaxel ◽  
Pathological Stage ◽  
Small Cell Lung ◽  
Stage Ib

scholarly journals Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study

2018 ◽  
Vol 10 (4) ◽  
pp. 2279-2287 ◽  
Author(s):  
Hye Jung Park ◽  
Heae Surng Park ◽  
Yoon Jin Cha ◽  
Sungsoo Lee ◽  
Hei-Cheul Jeung ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retrospective Study ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Ib ◽  
Resected Stage

Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer

2009 ◽  
Vol 5 (1) ◽  
pp. 19-22 ◽  
Author(s):  
Hossein Borghaei ◽  
Ranee Mehra ◽  
George Simon
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Ib ◽  
Resected Stage

scholarly journals P1.05-014 Efficacy of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small Cell Lung Cancer

2017 ◽  
Vol 12 (11) ◽  
pp. S1983
Author(s):  
M.K. Byun ◽  
H.J. Park ◽  
H.S. Park ◽  
H. Jeung ◽  
J.Y. Cho ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Ib ◽  
Resected Stage

scholarly journals Retrospective study of efficacy of adjuvant chemotherapy using tegafur-uracil in patients with non-small cell lung cancer with primary tumor size of 4.1–5.0 cm

2019 ◽  
Vol 11 (7) ◽  
pp. 3103-3111
Author(s):  
Hiroyuki Adachi ◽  
Teppei Nishii ◽  
Taketsugu Yamamoto ◽  
Takuya Nagashima ◽  
Yoshihiro Ishikawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retrospective Study ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Primary Tumor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Primary Tumor Size

Comparison of preoperative and prechemotherapy lymphocyte counts to predict outcome of non-small cell lung cancer patients treated with adjuvant chemotherapy.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20002-e20002
Author(s):  
Hyun Woo Lee ◽  
Yong Won Choi ◽  
Mi Sun Ahn ◽  
Seok Yun Kang ◽  
Jin-Hyuk Choi
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Surgical Resection ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Ib ◽  
Significant Difference ◽  
Histologic Types

e20002 Background: Several systemic inflammatory markers in blood have been suggested as prognostic factors in various cancers. We investigated the prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and absolute lymphocyte count (ALC) in patients (pts) with non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy. Methods: A retrospective review was conducted on 108 pts who received adjuvant chemotherapy after surgical resection of NSCLC. Disease-free survival (DFS) and overall survival (OS) of pts with high NLR and ALC ( > median value) before surgery or chemotherapy were compared to those of pts with low NLR and ALC (≤median value). Results: The number of pts at AJCC stage IB, IIA, IIB, IIIA, and IIIB were 1, 38, 9, 58, and 2, respectively. Adenocarcinoma, squamous cell carcinoma, and other histologic types were present in 66 (61.1%), 32 (29.6%), and 10 (9.3%) pts, respectively. The most frequently used chemotherapy regimen was vinorelbine/cisplatin (81 pts), followed by paclitaxel/carboplatin (22 pts), and others (5 pts). A total of 61 (56.5%) pts received adjuvant radiotherapy (before adjuvant chemotherapy: 53 pts). Preoperative NLR and ALC were not associated with clinicopathologic characteristics including stage and histologic types. High prechemotherapy NLR and low ALC were more frequently observed in pts who underwent radiotherapy before chemotherapy (p < 0.0001). The median follow-up duration was 70 (38-162) months for survivors. Pts with stage III demonstrated poor DFS (p = 0.019) and OS (p = 0.028) compared to those with stage IB or II. The shorter median DFS was observed in pts with low prechemotherapy ALC (20 vs. 65 months, p = 0.021), without significant difference in OS (p = 0.088). On the other hand, NLR and preoperative ALC were not associated with outcome of pts. Conclusions: The present study suggests that high prechemotherapy ALC is associated with poor outcome in stage IB-III NSCLC pts who received adjuvant chemotherapy after surgical resection.

Sign in / Sign up

Export Citation Format

Share Document